- Home
- NLSP vs SNGX Comparison
NLSP vs SNGX Comparison
Compare NLSP & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- SNGX
- Stock Information
- Founded
- NLSP 2015
- SNGX 1987
- Country
- NLSP Switzerland
- SNGX United States
- Employees
- NLSP N/A
- SNGX N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- SNGX Health Care
- Exchange
- NLSP Nasdaq
- SNGX Nasdaq
- Market Cap
- NLSP 6.9M
- SNGX 6.1M
- IPO Year
- NLSP 2021
- SNGX 1987
- Fundamental
- Price
- NLSP $1.49
- SNGX $2.21
- Analyst Decision
- NLSP
- SNGX
- Analyst Count
- NLSP 0
- SNGX 0
- Target Price
- NLSP N/A
- SNGX N/A
- AVG Volume (30 Days)
- NLSP 31.2K
- SNGX 29.1K
- Earning Date
- NLSP 05-14-2025
- SNGX 05-09-2025
- Dividend Yield
- NLSP N/A
- SNGX N/A
- EPS Growth
- NLSP N/A
- SNGX N/A
- EPS
- NLSP N/A
- SNGX N/A
- Revenue
- NLSP N/A
- SNGX $119,371.00
- Revenue This Year
- NLSP N/A
- SNGX N/A
- Revenue Next Year
- NLSP N/A
- SNGX N/A
- P/E Ratio
- NLSP N/A
- SNGX N/A
- Revenue Growth
- NLSP N/A
- SNGX N/A
- 52 Week Low
- NLSP $1.30
- SNGX $1.83
- 52 Week High
- NLSP $18.40
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- NLSP 42.38
- SNGX 42.26
- Support Level
- NLSP $1.30
- SNGX $2.25
- Resistance Level
- NLSP $1.60
- SNGX $2.28
- Average True Range (ATR)
- NLSP 0.10
- SNGX 0.11
- MACD
- NLSP 0.02
- SNGX -0.01
- Stochastic Oscillator
- NLSP 54.29
- SNGX 35.48
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).